We are live on ! Find out more

CAI

Caris Life Sciences

CAI

Market cap $7.24B

25.63 USD

-0.75

2.84%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

25.63

0.00

0%

1 day

-2.84%

5 days

-0.81%

1 month

64.4%

3 months

53.75%

6 months

24.06%

Year to date

-5%

1 year

-32.96%

5 years

-8.46%

10 years

-8.46%

About: Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Employees: 1,846

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Proactive Investors

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature.

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris Detect reinforce the durability and breadth of CAI's growth drivers. Valuation remains attractive and CAI trades at a discount to peers, with a fair value estimate of $30 per share by 2028.

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.54 per share a year ago.

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization.

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28% IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Reported total revenue of $263.7 million, an increase of 45% over the corresponding prior year period.

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection

Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implying ~35% upside, and 23%-26% 2026 estimated revenue growth. CAI's proprietary WES/WTS/WGS technology and massive data advantage underpin its leadership in oncology diagnostics and pharma R&D services. Short-term signals are net positive: insider buying, a $100M share repurchase program, and a bullish put-call ratio against a downward technical trend.

Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology for this disease.

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

See News Rankings

Price charts implemented using Lightweight Charts™